Marzena Odorczuk, MD
Internal Medicine · Totowa, NJNPI 1427153527
Payments from drug & device makers
Across 231 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$773
- AbbVie$706
- AstraZeneca$503
- Amgen$387
- Optinose US, Inc.$354
- Merck$216
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,89199%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $773 |
| AbbVie(2 entities) | 25 | $706 |
| AstraZeneca | 19 | $503 |
| Amgen | 19 | $387 |
| Optinose US, Inc. | 8 | $354 |
| Merck | 15 | $216 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $176 |
| Lilly USA, LLC | 12 | $170 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $152 |
| Phathom Pharmaceuticals, Inc. | 2 | $141 |
| Johnson & Johnson | 8 | $125 |
| Idorsia Pharmaceuticals US Inc | 8 | $123 |
| Exact Sciences | 2 | $121 |
| Vivus LLC | 7 | $114 |
| Boehringer Ingelheim | 8 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $105 |
| Kowa Pharmaceuticals America, Inc. | 5 | $75 |
| Centinel Spine, LLC | 1 | $67 |
| Amarin Pharma, Inc. | 5 | $66 |
| Astellas Pharma US Inc | 3 | $66 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| Pfizer | 3 | $53 |
| CSL Behring | 3 | $50 |
| IBSA Pharma Inc. | 3 | $42 |
| Endo Pharmaceuticals Inc. | 2 | $30 |
| Strongbridge US Inc. | 2 | $29 |
| Abbott | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Exeltis, USA Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,933 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $55,222 |
| ProliaDenosumab | 24 | $40,795 |
| EliquisApixaban | 31 | $29,104 |
| MounjaroTirzepatide | 24 | $27,557 |
| FarxigaDapagliflozin Propanediol | 14 | $17,428 |
| Repatha SureclickEvolocumab | 21 | $14,369 |
| JardianceEmpagliflozin | 19 | $14,113 |
| JanuviaSitagliptin Phosphate | 17 | $9,452 |
| OxycontinOxycodone Hcl | 12 | $8,306 |
| BelsomraSuvorexant | 18 | $7,851 |
| VascepaIcosapent Ethyl | 11 | $7,641 |
| SynthroidLevothyroxine Sodium | 34 | $3,207 |
| Omega-3 Acid Ethyl Esters | 26 | $1,552 |
| Rosuvastatin Calcium | 121 | $1,318 |
| Levothyroxine Sodium | 72 | $1,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $773 | $55,22246 claims |
| AmgenProlia | $387 | $40,79524 claims |
| PfizerEliquis | $53 | $29,10431 claims |
| Lilly USA, LLCMounjaro | $170 | $27,55724 claims |
| AstraZenecaFarxiga | $503 | $17,42814 claims |
| MerckJanuvia, Belsomra | $216 | $17,30335 claims |
| Boehringer IngelheimJardiance | $114 | $14,11319 claims |
| AbbVieSynthroid | $706 | $3,20734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Totowa
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.